GDF15 and congenital rubella syndrome: In the current study, the levels of suPAR and GDF-15 measured before the lymphodepleting therapy administration did not differ among the patients who developed severe CRS and/or ICANS post the infusion; in ROC analysis, these markers failed to predict the onset of severe complications.